VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

Context Therapeutics Inc. (CNTX) Total Return Calculator with Dividends Reinvested

Context Therapeutics Inc.

Popular:

The total return for Context Therapeutics Inc. (CNTX) stock is +207.81% over the past 12 months. So far it's up 53.55% this year. The 5-year total return is -53.33%, meaning $10,000 invested in CNTX stock 5 years ago would be worth $4,667 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in CNTX 1 year ago, it would be worth $30,474 today — you'd have gained $20,474.

With Dividends Reinvested$30,474+204.74%

Price Only (No DRIP)$30,474+204.74%

Period2025-05-09 → 2026-05-08

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in CNTX

1Y$30,781+$20,781 (+207.8%)207.8% CAGR

3Y$39,339+$29,339 (+293.4%)57.9% CAGR

5Y$4,667-$5,333 (-53.3%)-14.1% CAGR

10Y$4,667-$5,333 (-53.3%)-7.3% CAGR

15Y$4,667-$5,333 (-53.3%)-5.0% CAGR

20Y$4,667-$5,333 (-53.3%)-3.7% CAGR

30Y$4,667-$5,333 (-53.3%)-2.5% CAGR

Context Therapeutics Inc. did not pay dividends during this period. Total return = price return.

Loading CNTX total return...

As of 2026-05-09

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	+53.55%	—	+53.55%	—	$15,355
1Y	+207.81%	207.81%	+207.81%	—	$30,781
3Y	+293.39%	57.86%	+293.39%	—	$39,339
5Y	-53.33%	-14.14%	-53.33%	—	$4,667
10Y	-53.33%	-7.34%	-53.33%	—	$4,667
15Y	-53.33%	-4.95%	-53.33%	—	$4,667
20Y	-53.33%	-3.74%	-53.33%	—	$4,667
30Y	-53.33%	-2.51%	-53.33%	—	$4,667

Risk & Highlights

Best Year+67.63%2023

Worst Year-76.89%2022

Max Drawdown-32.74%2026-03-13 → 2026-04-20

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	+45.16%	+45.16%	—	+0.41%	+44.7pp
2025	+23.53%	+23.53%	—	+16.64%	+6.9pp
2024	-15.32%	-15.32%	—	+24.00%	-39.3pp
2023	+67.63%	+67.63%	—	+24.81%	+42.8pp
2022	-76.89%	-76.89%	—	-19.95%	-56.9pp

CNTX outperformed the S&P 500 by 177.27pp over the past year (+207.81% vs +30.54%).

Loading summary...

CNTX Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
CNTXContext Therapeutics Inc.	$219M	-9.8%	+53.5%	+207.8%	—	+293.4%	-53.3%	-53.3%
AGENAgenus Inc.	$135M	-9.0%	+18.3%	+25.7%	—	-88.0%	-93.7%	-94.2%
IMVTImmunovant, Inc.	$5.9B	+17.0%	+11.7%	+102.4%	—	+49.8%	+84.4%	+190.9%
ONCOOnconetix, Inc.	$1M	-67.6%	-95.5%	-98.8%	—	-100.0%	-100.0%	-100.0%
TPVGTriplePoint Venture Growth BDC Corp.	$234M	+14.3%	-9.6%	+7.4%	+16.0pp	-5.6%	-15.2%	+91.2%
AGIOAgios Pharmaceuticals, Inc.	$1.7B	-17.7%	+2.2%	-0.9%	—	+9.4%	-50.2%	-41.7%
SNDXSyndax Pharmaceuticals, Inc.	$1.9B	-12.5%	+0.9%	+95.2%	—	+5.9%	+37.4%	+50.1%
RCUSArcus Biosciences, Inc.	$2.6B	+12.0%	+8.9%	+197.3%	—	+27.8%	-12.1%	+49.2%
PRMEPrime Medicine, Inc.	$580M	-9.3%	-9.1%	+143.2%	—	-77.3%	-79.1%	-54.9%
RVMDRevolution Medicines, Inc.	$30.1B	+46.6%	+79.5%	+238.4%	—	+480.2%	+375.9%	+390.7%
NUVLNuvalent, Inc.	$7.7B	+0.2%	+4.4%	+47.0%	—	+178.8%	+461.5%	+461.5%

Compare:CNTX vs AGEN CNTX vs IMVT CNTX vs ONCO CNTX vs AGEN vs IMVT

About CNTX Dividend Returns

Context Therapeutics Inc. (CNTX) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of CNTX over the past year?

Context Therapeutics Inc. (CNTX) delivered a return of 207.81% over the past year. Since CNTX does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in CNTX be worth today?

A $10,000 investment in Context Therapeutics Inc. one year ago would be worth $30,781 today, representing a gain of $20,781.

Q3Does CNTX pay dividends?

Context Therapeutics Inc. (CNTX) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For CNTX, the total return equals the price-only return.

Q4Did CNTX beat the S&P 500?

Yes, Context Therapeutics Inc. (CNTX) outperformed the S&P 500 by 177.27 percentage points over the past year. CNTX delivered a total return of 207.81%, compared to the S&P 500's 30.54%. This 177.27pp alpha means investors in CNTX earned more than a passive S&P 500 index fund.

Q5What is CNTX's worst drawdown?

Context Therapeutics Inc. (CNTX) experienced a maximum drawdown of -32.74% over the past year, declining from its peak on 2026-03-13 to its trough on 2026-04-20. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is CNTX's long-term total return over 10, 20, or 30 years?

Here are Context Therapeutics Inc. (CNTX)'s long-term returns with dividends reinvested. Over 10 years, the total return is -53.3% (-7.3% CAGR) — $10,000 would have grown to $4,667. Over 20 years: -53.3% total return (-3.7% CAGR) — $10,000 → $4,667. Over 30 years: -53.3% total return (-2.5% CAGR) — $10,000 → $4,667. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was CNTX's best and worst year?

Context Therapeutics Inc.'s best calendar year was 2023 with a total return of 67.6%. Its worst year was 2022 with a total return of -76.9%. This range shows the volatility investors should expect — the difference between the best and worst year is 144.5 percentage points.